


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of the claims and listing of the claims in the application:

1.-13. (Cancelled)

14. (Currently Amended) A method for treating a subject for glaucoma, comprising administering a therapeutically effective amount of a deprenyl compound to a subject, The method of claim 1, wherein the deprenyl compound is represented by the structure:



in which

R₁ is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxy carbonyl;

R₂ is hydrogen or alkyl;


R₃ is a bond or methylene; and

R₄ is aryl or aralkyl; or

R₂ and R₄-R₃ are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group;

and pharmaceutically acceptable salts thereof.

15. (Currently Amended) A method for treating a subject for glaucoma, comprising administering a therapeutically effective amount of a deprenyl compound to a subject, The method of claim 1, wherein the deprenyl compound is represented by the structure:



in which

R₂ is hydrogen or alkyl;

R₃ is a bond or methylene; and


R₄ is aryl or aralkyl; or

R₂ and R₄-R₃ are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group; and

R₅ is alkylene, alkenylene, alkynylene and alkoxylenes;

and pharmaceutically acceptable salts thereof.

16. **(Currently Amended)** A method for treating a subject for glaucoma, comprising administering a therapeutically effective amount of a deprenyl compound to a subject. The method of claim 1, wherein the deprenyl compound is represented by the structure:



in which

R₁ is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxy carbonyl, or aryloxy carbonyl;

A is a substituent independently selected for each occurrence from the group consisting of halogen, hydroxyl, alkyl, alkoxy, cyano, nitro, amino, carboxyl, -CF₃, or azido;

n is 0 or an integer from 1 to 5;

and pharmaceutically acceptable salts thereof.

17.-20. **(Cancelled)**

21. **(New)** The method of claim 14, wherein said therapeutically effective amount of a deprenyl compounds is administered with a pharmaceutically acceptable carrier.

22. (New) The method of claim 21, wherein said pharmaceutically acceptable carrier has a pH of between about 3 and about 5.
23. (New) The method of claim 22, wherein said pharmaceutically acceptable carrier is an alcohol or aqueous alcohol solution.
24. (New) The method of claim 21, wherein said pharmaceutically acceptable carrier is suitable for ophthalmic administration.
25. (New) The method of claim 14, wherein said subject is a human.
26. (New) The method of claim 15, wherein said therapeutically effective amount of a deprenyl compounds is administered with a pharmaceutically acceptable carrier.
27. (New) The method of claim 26, wherein said pharmaceutically acceptable carrier has a pH of between about 3 and about 5.
28. (New) The method of claim 26, wherein said pharmaceutically acceptable carrier is an alcohol or aqueous alcohol solution.
29. (New) The method of claim 28, wherein said pharmaceutically acceptable carrier is suitable for ophthalmic administration.
30. (New) The method of claim 15, wherein said subject is a human.
31. (New) The method of claim 16, wherein said therapeutically effective amount of a deprenyl compounds is administered with a pharmaceutically acceptable carrier.

32. (New) The method of claim 31, wherein said pharmaceutically acceptable carrier has a pH of between about 3 and about 5.
33. (New) The method of claim 31, wherein said pharmaceutically acceptable carrier is an alcohol or aqueous alcohol solution.
34. (New) The method of claim 31, wherein said pharmaceutically acceptable carrier is suitable for ophthalmic administration.
35. (New) The method of claim 16, wherein said subject is a human.